We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.875 | 418,604 | 15:20:02 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 5.75 | 6.00 | 5.875 | 5.75 | 5.875 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.29 | 6.62M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:21:29 | O | 50,000 | 5.9925 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/4/2024 | 17:00 | UK RNS | Genedrive PLC Application for Listing & Total Voting Rights |
| 03/4/2024 | 11:49 | ALNC |  Genedrive shares surge as UK's NICE backs test for ischaemic stroke |
| 03/4/2024 | 07:00 | UK RNS | Genedrive PLC NICE recommends the Genedrive CYP2C19-ID Kit |
| 28/3/2024 | 14:35 | ALNC | EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate |
| 28/3/2024 | 07:00 | UK RNS | Genedrive PLC Half-year Report |
| 26/3/2024 | 07:00 | UK RNS | Genedrive PLC Investor presentation |
| 19/3/2024 | 15:53 | UK RNS | Genedrive PLC Application for Listing & Total Voting Rights |
| 15/3/2024 | 13:50 | ALNC | Genedrive down as plans equity raise despite GBP800,000 tax credit |
| 15/3/2024 | 12:30 | UK RNS | Genedrive PLC Receipt of R&D tax credit |
| 19/2/2024 | 18:57 | ALNC | TRADING UPDATES: Coro seals sale terms, Powerhouse makes good progress |
Genedrive (GDR) Share Charts1 Year Genedrive Chart |
|
1 Month Genedrive Chart |
Intraday Genedrive Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/4/2024 | 10:26 | Genedrive, A Game Changer for Point of Care Testing Market? | 3,564 |
| 10/4/2024 | 15:17 | is share price move coming soon | 102 |
| 29/8/2023 | 10:05 | Genedrive. A Game Changer for Global Covid 19 Testing Market? | 18,732 |
| 15/6/2023 | 07:59 | Genedrive (GDR) One to Watch | 1,880 |
| 22/2/2022 | 22:22 | COVID-19 BULL FREE | 100 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:21:30 | 5.99 | 50,000 | 2,996.25 | O |
| 14:20:03 | 6.00 | 7,479 | 448.74 | O |
| 14:20:02 | 5.75 | 26 | 1.50 | O |
| 14:20:02 | 6.00 | 500 | 30.00 | O |
| 14:20:02 | 5.75 | 11 | 0.63 | O |
| Top Posts |
|---|
Posted at 19/4/2024 09:20 by Genedrive Daily Update Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 5.88p.Genedrive currently has 115,139,946 shares in issue. The market capitalisation of Genedrive is £6,620,547. Genedrive has a price to earnings ratio (PE ratio) of -1.29. This morning GDR shares opened at 5.88p |
Posted at 04/4/2024 13:40 by kingston78 Placing shares at a discount is not an issue because it will secure the company's finances to develop the business. Sometimes, placing is at a premium to a small group of keen investors because they can see the upside. If they were to buy shares in the open market they would push up the price anyway.I suspect that the company will announce placing of shares next, then followed by a positive commercial deal in the US. The share price will fly. |
Posted at 04/4/2024 09:26 by indomie1 Still only sitting at the recent 6p mgmt share options incentive plan price. There was huge uncertainty around GDR until the last week, which took the share price down to crazy rock bottom prices. Now with the exception of the preferred funding package/partner, this has largely been addressed with all the recent updates. |
Posted at 28/3/2024 09:03 by thecroots I honestly don't know how they are going to raise anything of significant value. When they did the reverse placing when the share price was 30p, the CEO said that was the only option at the time. Since then, the share price has collapsed 90%. Therefore, for that reason i can only see continuation of reverse placing as the only option. |
Posted at 26/3/2024 12:50 by terminator101 Except gdr is troughs and even deeper troughs. Mate there are only a few 100% certainties:1. Taxes2.death3. A Share price will fall after death spiral finance is announced. |
Posted at 22/3/2024 16:46 by hazl Where were you yesterday,son?You're just a coward,hiding behind a pseudonym. I didn't need a warning. I knew exactly what I was doing....supporting a company in it's hour of need. I believe the share would have been even lower without the supporters here. Investors, who are not only hopeful of a company gaining credit in the end by becoming commercial, or being taken out, but with a rising share price to boot! Yes, it did resort to a dreadful loan, known to reduce the share price, but it gave it time to impress the medical staff....who openly praise GDR's products and can see their value and indeed time to get further down the road of the important accreditations. My IQ is neither here nor there but it is a well known tactic of shorters to attempt to discredit the most supportive poster, on a company, that they have targetted. It is also typical of a shorter to hide in the bushes, when the share is flying which you did yesterday. Not only heartless but also a wimp! |
Posted at 22/3/2024 10:24 by bones698 Heading back sub 4p again as the traders jump ship. Just traders moving this as no news. Think it will see 3.5p again.Commercialisation will take years and Gdr simply don't have the money and need to raise to get to break even. That's been the problem here and why the share price has crashed from over 25p to just over 3p. |
Posted at 15/3/2024 07:08 by aquilla Bones 698, Whilst I agree that GDR has proved a disastrous investment thus far, I would disagree on two issues you raise.Firstly you talk about a dilutive fund raise. Not necessarily. From last year's Finals: "As well as equity or debt financing we are also actively seeking non-dilutive funding such as grants, funding partners for the FDA approval and charitable organisations willing to support the adoption of our quality-of-life enhancing innovations." Secondly, you state: "I see no reason the decline will stop" The CEO expressed several aspirations/forecast But, for the moment, the jury is out on whether there is a viable future for Genedrive or not and that is reflected in the share price. |
Posted at 21/2/2024 12:28 by angus17 brave man. I have been a long term holder and took half out yesterday. I have been so badly burned by several other aim companies in the past I had to salvage something just in case it is going to completely fail.The share price graph says it all sadly. gamble money left in. Got a little lucky last week with RENX. and sold just at the right time. Shows that crazy share price movements can happen. |
Posted at 20/2/2024 11:52 by indomie1 In light of all the positive news, maybe other financing options are now opening up that are more attractive than the RF drawdown facility. Given share price falls, another 35-40m shares cud be issued for the £1.5m still available (if got my maths right!). That's a huge chunk of the company to sell off, with more needed again given current delays. The products have proven themselves, there's just insufficient evidence of long term demand/contracts at present, hence the current share price They could do a sale at 10-20p but really need NICE approvals or commissioning to get a decent take out price here for owners/investors. If nothing is forthcoming, stock holders will need to dig deep to keep the show on the road! |
Posted at 05/2/2024 14:08 by the imperialist "indomie1 - 31 Mar 2023 - 18:52:42 - 1810 of 1881 Genedrive (GDR) One to Watch - GDRWow! Derampers clutching at straws here! AIHL market in UK now estimated to be worth £8m a year, up from £5m. If NHS were minded to provide funding for that test to accelerate rollout then GDR will surely hit B/E on UK sales alone! Thats without sales from EU, US or ROW. Then we have another new rapid genomic test, to be launched off the back of NICE in the Autumn with a global market in excess of £200m! As a pioneer in the rapid genomic testing space, this is a really exciting space for any Medtech firm to be in! Funding for at least next 12 months secured and who knows what other surprises GDR have up their sleave! :-) Hopefully now GDR will be able to tempt some longer term institutional investors onto the share register! This company deserves to be in a better market than AIM! GLA" |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
